Characterization of five newly derived canine osteosarcoma cell lines.
Adipogenesis
Alkaline Phosphatase
/ biosynthesis
Animals
Antineoplastic Agents
/ pharmacology
Cell Line, Tumor
/ cytology
Cell Proliferation
Chondrogenesis
Cisplatin
/ pharmacology
Culture Media
Dog Diseases
/ metabolism
Dogs
Female
Heterografts
/ metabolism
Mice
Neoplasm Invasiveness
Neoplasm Transplantation
Osteogenesis
Osteosarcoma
/ metabolism
Canine
Cell line
Osteosarcoma
Xenograft
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
22 Oct 2019
22 Oct 2019
Historique:
received:
04
02
2019
accepted:
20
09
2019
entrez:
24
10
2019
pubmed:
24
10
2019
medline:
18
2
2020
Statut:
epublish
Résumé
Canine and human osteosarcomas (OS) are notably similar and have a high rate of metastasis. There is a poor understanding of the tumor development process, predisposing causes, and varying levels of aggression among different cell lines. By characterizing newly developed canine osteosarcoma cell lines, treatments for people and pets can be developed. Of the seven subtypes of OS, three are represented in this group: osteoblastic (the most common), fibroblastic, and giant cell variant. To our knowledge, there are no other giant cell variant canine OS cell lines in the published literature and only one canine fibroblastic osteosarcoma cell line. Understanding the differences between the histologic subtypes in dogs will help to guide comparative research. Alkaline phosphatase expression was ubiquitous in all cell lines tested and invasiveness was variable between the cell lines tested. Invasiveness and oxidative damage were not correlated with in vivo growth rates, where TOT grew the fastest and had the higher percentage of mice with metastatic lesions. TOL was determined to be the most chemo-resistant during cisplatin chemotherapy while TOM was the most chemo-sensitive. Further comparisons and studies using these cell lines may identify a variety of characteristics valuable for understanding the disease process and developing treatments for osteosarcoma in both species. Some of this data was presented as a poster by KMF at the August 5th, 2017 National Veterinary Scholars Program in Bethesda, MA. Characterization of 5 newly generated canine osteosarcoma cell lines. Kelli Franks, Tasha Miller, Heather Wilson-Robles.
Sections du résumé
BACKGROUND
BACKGROUND
Canine and human osteosarcomas (OS) are notably similar and have a high rate of metastasis. There is a poor understanding of the tumor development process, predisposing causes, and varying levels of aggression among different cell lines. By characterizing newly developed canine osteosarcoma cell lines, treatments for people and pets can be developed. Of the seven subtypes of OS, three are represented in this group: osteoblastic (the most common), fibroblastic, and giant cell variant. To our knowledge, there are no other giant cell variant canine OS cell lines in the published literature and only one canine fibroblastic osteosarcoma cell line. Understanding the differences between the histologic subtypes in dogs will help to guide comparative research.
RESULTS
RESULTS
Alkaline phosphatase expression was ubiquitous in all cell lines tested and invasiveness was variable between the cell lines tested. Invasiveness and oxidative damage were not correlated with in vivo growth rates, where TOT grew the fastest and had the higher percentage of mice with metastatic lesions. TOL was determined to be the most chemo-resistant during cisplatin chemotherapy while TOM was the most chemo-sensitive.
CONCLUSIONS
CONCLUSIONS
Further comparisons and studies using these cell lines may identify a variety of characteristics valuable for understanding the disease process and developing treatments for osteosarcoma in both species. Some of this data was presented as a poster by KMF at the August 5th, 2017 National Veterinary Scholars Program in Bethesda, MA. Characterization of 5 newly generated canine osteosarcoma cell lines. Kelli Franks, Tasha Miller, Heather Wilson-Robles.
Identifiants
pubmed: 31640712
doi: 10.1186/s12917-019-2099-y
pii: 10.1186/s12917-019-2099-y
pmc: PMC6805340
doi:
Substances chimiques
Antineoplastic Agents
0
Culture Media
0
Alkaline Phosphatase
EC 3.1.3.1
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
357Subventions
Organisme : NIH HHS
ID : 5T35OD010991.
Pays : United States
Références
Breast Cancer Res. 2003;5(2):89-95
pubmed: 12631387
J Carcinog. 2006 May 11;5:14
pubmed: 16689993
Acta Vet Scand. 2017 Oct 24;59(1):71
pubmed: 29065898
Lab Invest. 2011 Aug;91(8):1195-205
pubmed: 21519327
Adv Exp Med Biol. 2014;804:237-56
pubmed: 24924178
Yale J Biol Med. 1979 Jul-Aug;52(4):345-61
pubmed: 115162
Vet Clin North Am Small Anim Pract. 1985 May;15(3):609-41
pubmed: 3892872
Vet J. 2011 Sep;189(3):268-77
pubmed: 20889358
Vet J. 2008 Jan;175(1):69-75
pubmed: 17851099
PLoS One. 2014 Jan 08;9(1):e83144
pubmed: 24416158
J Cancer. 2011 May 04;2:262-70
pubmed: 21552385
J Vet Med Sci. 1998 Jun;60(6):757-60
pubmed: 9673952
Clin Orthop Relat Res. 2007 Jun;459:40-7
pubmed: 17414166
Molecules. 2018 Aug 03;23(8):null
pubmed: 30081476
BMC Genomics. 2009 Dec 23;10:625
pubmed: 20028558
Int J Mol Sci. 2016 Aug 31;17(9):
pubmed: 27589734
Mol Cancer. 2009 Sep 07;8:72
pubmed: 19735553
Front Oncol. 2014 Jul 18;4:189
pubmed: 25101245
Curr Protoc Pharmacol. 2007 Jun;Chapter 14:Unit 14.1
pubmed: 21948160
Stem Cell Rev Rep. 2017 Jun;13(3):347-363
pubmed: 28233276
Anticancer Res. 2007 Jan-Feb;27(1A):155-64
pubmed: 17352227
Am J Pathol. 2002 Feb;160(2):403-8
pubmed: 11839558
Pediatr Blood Cancer. 2012 Mar;58(3):327-33
pubmed: 21990244
Endocr Relat Cancer. 2005 Mar;12(1):19-47
pubmed: 15788637